(KM) with Stargazin at -60 (blue) and +50 mV (red). Superimposition of the traces showed a substantially smaller apparent effect of Stargazin at negative potentials compared to positive potentials. The desensitization and deactivation rates measured at negative potentials were significantly faster than those measured at positive potential (k des = 40 ± 2 and 80 ± 15, p = 0.0011, 40 and 60 s -1 in this example; k deact = 350 ± 30 and 1740 ± 220, p = 0.00026, 150 and 2200 s -1 in this example, n = 16 and 6, at +50 and -60 mV respectively). Similarly, the effect of Stargazin on the steady state current was reduced at negative potentials (in this example, I ss = 15 and 45 % at -60 and +50 mV, respectively). (D) At negative potentials, some patches showed a decrease in the effect of Stargazin on GluA2 WT with time (orange t = 0 s, blue t = 5 s, green t = 10 s and red t = 20 s). For the patch shown in the figure, the desensitization rate increased from 50 s -1 at t = 0 to 120 s -1 at t = 20 s. The latter value is the same as k des for GluA2 WT alone. The same patch at positive potential showed no change in the kinetics of the normalized current, with stable k des of 46 ± 1.5 s -1 and steady-state current of 15 ± 2 %, over an equivalent series of applications. This effect suggested that, in some patches, Stargazin containing complexes were lost over time. pA at -60 mV, n = 5), whereas the peak current was about 20-times larger at -60 mV than at +50 mV (30 ± 5 pA at +50 mV and 600 ± 150 pA at -60 mV, n = 5).
Supplementary
Expressed as a ratio, the magnitude of the superactivation currents (comparing +50 mV with -60 mV) was on average 0.43 ± 0.1, whereas the same ratio for initial peak currents was 0.06 ± 0.02. All comparisons were made with a non-parametric The decay of the current is significantly slower at the end of the train stimulation for GluA2-γ -8 (n = 9) but remains unchanged for GluA2 alone (n = 4). Error bars represent s.e.m. 
